Numerous Catalysts Ahead....Nasdaq press release Aleafia Health has been making tremendous progress on its own initiatives apart from the Emblem merger. During the third quarter of 2018, the company indicated that the fully-funded retrofitting of its 160,000 sq. ft. Niagara greenhouse facility and outdoor expansion was on schedule. Management anticipates that these efforts will result in an annual production capacity of 98,000 kilograms, making it one of the larger licensed producers in Canada.
In addition to improving production capacity, the company continues to invest in patient education as a key differentiator. The company has developed and implemented a proprietary training program for all of its staff to help those with chronic medical conditions that have failed first, second, and often, third line approaches. The training program extends to both internal and partner clinics to service a maximum amount of patients.
The company also continues to make waves in the medical cannabis research space. With more than 60,000 patients, the company has amassed one of the largest medical cannabis datasets in the world, enabling researchers to validate cannabis sciences, product teams to develop innovative new products, and management to build a strong IP portfolio. In the third quarter, this division contributed $612,000 to revenue.
Click Here to Download Aleafia Health Inc.'s Investor Presentation
Looking Ahead
Aleafia Health Inc. (TSX: ALEF) (OTC:ALEAF) (FRA: ARAH) is well positioned within Canada's nascent cannabis industry following its merger with Emblem. With robust patient growth, high margin products, and growing revenue, investors may want to take a closer look at the combined company ahead of several potential catalysts.
https://www.nasdaq.com/press-release/aleafia-health--emblem-merger-creates-a-new-cannabis-leader--cfn-media-20190321-00274